The effects of edaravone combined with breviscapine treatment on MCP-1 expression in the cerebral cortex after focal cerebral ischemia in rats
LI Fan, CHEN Wei-wei, ZHAO Xiao-shu, ZENG Hong-yan, HAN Hong, SONG Yong-li, YUAN Yun, WU Chun-yun
Chinese Journal of Clinical Anatomy ›› 2018, Vol. 36 ›› Issue (1) : 38-44.
The effects of edaravone combined with breviscapine treatment on MCP-1 expression in the cerebral cortex after focal cerebral ischemia in rats
Objective This research investigated the expression of MCP-1 in cerebral cortex of rat following middle cerebral artery occlusion (MCAO) and edaravone combination with breviscapine as a treatment of MCP-1 expression. Methods Animal models of MCAO were established， and RT-PCR，Western blot and Immunohistochemistry were used to detect the expression of MCP-1 in cerebral cortex of rats after MCAO and drug intervention. Results The expression of MCP-1 mRNA were significantly enhanced after MCAO, and became most severe at 12 h, and the difference was significant (P<0.05). The expression of MCP-1 mRNA was markedly decreased compared with the saline group after drug treatment (P<0.05)； The combination of edaravone plus breviscapine was more effective than edaravone or breviscapine treatment alone (P<0.05). The expression of MCP-1 protein was significantly increased in 1d, 3d, 1 week following MCAO and stayed at a high level (P<0.05), and than obviously decreased compared with the saline group after drug treatment (P<0.05); the combination of edaravone plus breviscapine was more effective than edaravone or breviscapine alone (P<0.05) . Immunofluorescence staining showed that activated microglial cells was co-labeled with MCP-1 positive cells, and the number of MCP-1 positive cells was significantly increased after MCAO peaking at 1week. By the mean time, microglial cells did not exhibit MCP-1 positive cells in saline group. Conclusion Edaravone combination with breviscapine as a treatment could decrease the MCP-1 expression after cerebral ischemia, and the combination of edaravone plus breviscapine is more effective than edaravone or breviscapine alone.
Cerebral ischemia; Breviscapine; Edaravone; Monocyte chemotactic protein 1 / Rats
[1] Fukuda S, Fini CA, Mabuchi T, et al. Focal cerebral ischemia induces active proteases that degrade microvascular matrix [J]. Stroke, 2004, 35(4):998-1004.
[2] Abraham S, Sawaya BE, Safak M, et al. Regulation of MCP-1 gene transcription by Smads and HIV-1 Tat in human glial [J]. cells Virology, 2003, 309(2):196-202.
[3] Britschgi M, Wyss Coray T. Immune cells may fend off Alzheimer disease [J]. Nat Med, 2007, 13(4):408-409.
[4] 卢展宏, 石显婷. 依达拉奉联合吡拉西坦注射液治疗急性病毒性脑炎的临床观察[J]. 中国医药前沿, 2010, 5(8):17.
[5] Tamura A, Graham DI, McCulloch J, et al. Focal cerebral ischaemia in the rat:1. Description of technique and early neuropathological consequences following middle cerebral artery occlusion [J]. Cereb Blood Flow Metab, 1981, 1(1):53-60.
[6] Arakelyan A, Petrkova J, Hermanova Z, et al. Serum levels of the MCP-1 chemokine in patients with ischemic stroke and myocardial infarction[J]. Mediators Inflamm, 2005, 2005(3):175-179.
[7] Bobcock AA, Kuziel WA, Rivest S, et al. Chemokine expression by glial cells directs leukocytes to sites of axonal injury in the CNS [J]. Neuroscience, 2003, 23(21):7922-7930.
[8] Guyon A, Skrzydelski D, De Giry I, et al. Long term exposure to the chemokine CCL2 activates the nigrostriatal dopamine system: a novel mechanism for the control of dopamine release [J]. Neuroscience, 2009, 162(4):1072-1080.
[9] Muldoon LL, Alvarez JI, Begley DJ, et al. Immunologic privilege in the central nervous system and the blood-brain barrier [J]. Cereb Blood Flow Metab, 2013, 33(1):13-21.
[10]Haseloff RF, Blasig IE, Bauer HC, et al. In search of the astrocytic factor(s) modulating blood-brain barrier functions in brain capillary endothelia cells in vitro [J]. Cell Mol Neurobiol, 2005, 25(1): 25-39.
[11]Kumai Y, Ooboshi H, Takada J, et al. Anti-monocyte chemoattractant protein-1gene therapy protects against focal brain ischemia in hypertensive rats [J]. Cereb Blood Flow Metab, 2004, 24(12):1359-1368.
[12]Gourmala NG, Buttini M, Limonta S, et al. Differential and time-dependent expression of monocyte chemoattractant protein-1 mRNA by astrocytes and macrophages in rat brain: effects of ischemia and peripheral lipopolysaccharide administration [J]. J Neuroimmunol, 1997, 74(1-2):35-44.
[13]Tanaka M. Pharmacdogical and clinical profile of the free radical scavenger daravone as a neuroprotective agent [J]. Nihon Yakurigaku Zasshi, 2002, 119: 301-308.
[14]Uno M, Kitazato KT, Suzue A, et al. Inhibition of brain damage by edaravone, a free radical scavenger, can be monitored by plasma biomarkers that detect oxidative and astrocyte damage in patients with acute cerebral infarction [J]. Free Radic Biol Med, 2005, 39(8):1109-1116.
[15] Eiichi O. Effect of a novel free radical scavenger edaravone (MCI-186)on acute brain infarction [J]. Cerebrovasc Dis, 2003, 15(3):222-229.
[16] 封亮, 聂志余, 詹青, 等. 依达拉奉对脑缺血再灌注大鼠的神经保护作用及其机制的研究[J]. 脑与神经疾病杂志, 2012, 20(4): 283-287.
[17] 张明艳, 范淑娟，李利平，等. 灯盏花注射液抗新生鼠缺氧缺血性脑损伤的作用及对Bcl-2、Bax蛋白表达的影响[J]. 中国应用生理学杂志, 2011, 27(2): 196-200.
[18] Guo C, Zhu Y, Weng Y, et al. Therapeutic time window and underlying therapeutic mechanism of breviscapine injection against cerebral ischemia/reperfusion injury in rats [J]. J Ethnopharmacol, 2014, 151(1): 660-666.
/
| 〈 |
|
〉 |
